S
Srinivas K. Tantravahi
Researcher at Huntsman Cancer Institute
Publications - 72
Citations - 1156
Srinivas K. Tantravahi is an academic researcher from Huntsman Cancer Institute. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 53 publications receiving 928 citations. Previous affiliations of Srinivas K. Tantravahi include University of Utah & Gandhi Institute of Technology and Management.
Papers
More filters
Journal ArticleDOI
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Matthew S. Zabriskie,Christopher A. Eide,Christopher A. Eide,Srinivas K. Tantravahi,Nadeem A. Vellore,Johanna Estrada,Franck E. Nicolini,Hanna Jean Khoury,Richard A. Larson,Marina Konopleva,Jorge E. Cortes,Hagop M. Kantarjian,Elias J. Jabbour,Steven M. Kornblau,Jeffrey H. Lipton,Delphine Rea,Leif Stenke,Gisela Barbany,Thoralf Lange,Juan Carlos Hernández-Boluda,Gert J. Ossenkoppele,Richard D. Press,Charles Chuah,Stuart L. Goldberg,Meir Wetzler,François Xavier Mahon,Gabriel Etienne,Michele Baccarani,Simona Soverini,Gianantonio Rosti,Philippe Rousselot,Ran Friedman,Marie Deininger,Kimberly R. Reynolds,William L. Heaton,Anna M. Eiring,Anthony D. Pomicter,Jamshid S. Khorashad,Todd W. Kelley,Riccardo Baron,Brian J. Druker,Brian J. Druker,Michael W. Deininger,Thomas O'Hare +43 more
TL;DR: These findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome, and in vitro resistance profiling was predictive of treatment outcomes in Ph(+) leukemia patients.
Journal ArticleDOI
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
Rana R. McKay,Nils Kroeger,Nils Kroeger,Wanling Xie,Jae-Lyun Lee,Jennifer J. Knox,Georg A. Bjarnason,Mary J. MacKenzie,Lori Wood,Sandy Srinivas,Ulka N. Vaishampayan,Sun Young Rha,Sumanta K. Pal,Frede Donskov,Srinivas K. Tantravahi,Brian I. Rini,Daniel Y.C. Heng,Toni K. Choueiri +17 more
TL;DR: The presence of bone metastases and LMs in patients treated with targeted agents has a negative impact on survival and patients with BMs and/or LMs may benefit from earlier inclusion on clinical trials of novel agents or combination-based therapies.
Journal ArticleDOI
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
Anna M. Eiring,Brent D. G. Page,Ira L. Kraft,Clinton C. Mason,Nadeem A. Vellore,Diana Resetca,Matthew S. Zabriskie,Tian Y. Zhang,Jamshid S. Khorashad,A J Engar,Kimberly R. Reynolds,David J. Anderson,Anna V. Senina,Anthony D. Pomicter,Carolynn C. Arpin,S Ahmad,William L. Heaton,Srinivas K. Tantravahi,A Todic,Robert Colaguori,Richard Moriggl,Derek J. Wilson,Riccardo Baron,Thomas O'Hare,Patrick T. Gunning,Michael W. Deininger +25 more
TL;DR: The findings implicate STAT3 as a critical signaling node in BCR-ABL1 kinase-independent TKI resistance, and suggest that BP-5-087 has clinical utility for treating malignancies characterized by STAT3 activation.
Journal ArticleDOI
Age-related mutations and chronic myelomonocytic leukemia.
Clinton C. Mason,Jamshid S. Khorashad,Srinivas K. Tantravahi,Todd W. Kelley,Matthew S. Zabriskie,Dongqing Yan,Anthony D. Pomicter,Kimberly R. Reynolds,Anna M. Eiring,Zev N. Kronenberg,Recinda L. Sherman,Jeffrey W. Tyner,Brian Dalley,Kim Hien T. Dao,Mark Yandell,B. J. Druker,Jason Gotlib,Thomas O'Hare,Thomas O'Hare,Michael W. Deininger,Michael W. Deininger +20 more
TL;DR: Age-adjusted population incidence and reported ARCH mutation rates are consistent with a model in which clinical CMML ensues when a sufficient number of stochastically acquired age-related mutations has accumulated, suggesting that CMML represents the leukemic conversion of the myelomonocytic-lineage-biased aged hematopoietic system.
Journal ArticleDOI
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Jamshid S. Khorashad,Anna M. Eiring,Clinton C. Mason,Kevin C. Gantz,Amber D. Bowler,Hannah M. Redwine,Fan Yu,Fan Yu,Ira L. Kraft,Anthony D. Pomicter,Kimberly R. Reynolds,Anthony J. Iovino,Matthew S. Zabriskie,William L. Heaton,Srinivas K. Tantravahi,Michael Kauffman,Sharon Shacham,Alex Chenchik,Kyle Bonneau,Katharine S. Ullman,Thomas O'Hare,Michael W. Deininger +21 more
TL;DR: Data implicate RAN in BCR-ABL1 kinase-independent imatinib resistance and show that shRNA library screens are useful to identify alternative pathways critical to drug resistance in CML.